API Purification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

API Purification
Pharmaceutical Technology Europe speaks to Peter Koklitis, a technical filtration specialist at 3M's purification division, about the latest trends, techniques and technologies in API purification.


Pharmaceutical Technology Europe
Volume 23, Issue 9

What are the process challenges involved in API filtration and purification?

The increased need to fast track APIs to market and to minimise validation activities, although challenging, has presented significant opportunities for new product developments in purification. The requirement to remove any residual metal catalyst from API synthetic process streams co-exists with the drive to establish modular platforms for flexibility and scale-up; thus, once an effective metal adsorbent is identified, the process scale-up requirements must be considered. The use of adsorbents in bulk powder form has inherent disadvantages, particularly when scaling up for production operation (i.e., dust handling, personal protection and equipment cleaning). In some instances, the metal adsorbent selected for pilot scale operations is found to be unsuitable at a larger production scale because of cost considerations or fundamental changes in process step conditions, for example. The adsorption of metal species is influenced by temperature, pH and solvent composition; therefore it is often necessary to re-consider the choice of adsorbent if any or all of these conditions change for scale up following process optimisation. The use of chemically aggressive solvents, such as acetone, tetrahydrofuran and dimethylformamide, in API manufacture, although not preferred, may also be required for catalytic synthetic steps. Consequently, these can present compatibility challenges to the material components of the systems.

The move to having flexible scalable systems for process filtration has also influenced the development of filter products to provide modular solutions. The use of filter media impregnated by adsorbent powder, such as activated carbon modules, to avoid the use of bulk powder handling has been widened to consider how other adsorbent materials or speciality metal scavengers can be similarly immobilised. This approach can only be successful when the adsorptive properties are not impaired by the immobilisation procedure. Laboratory and pilot laboratory testing can confirm efficacy and also accurately size area requirements for process scale up. The cost of implementation can be offset by the removal of what will become redundant existing filtration steps, previously used for the bulk powder removal.

In API bioprocessing, host cell impurity removal at clarification and in downstream processing is an area of focus and the use of charged membranes as encapsulated capsules could decrease expensive chromatography column usage. The adoption of single-use systems in bioprocessing process steps is generally not restricted through chemical compatibility issues, as seen with synthetic API processes. However, alkali-resistant capsules are required in bioprocessing manufacturing if caustic solutions are used for validated depyrogenation procedures.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here